Grading ductal carcinoma in situ of the breast using an automated proliferation index

Annals of Clinical and Laboratory Science

Volumn 41, Issue 2, 2011, Pages 122-130

  Stasik, Christopher J ^a   Davis, Marilyn ^a   Kimler, Bruce F ^a   Fan, Fang ^a   Damjanov, Ivan ^a   Thomas, Patricia ^a   Tawfik, Ossama W ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Automation; Ductal carcinoma in situ; Grading

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P21; PROTEIN P27; PROTEIN P53;

ARTICLE; CANCER GRADING; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; INTRADUCTAL CARCINOMA; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NUCLEAR GRADE PROLIFERATION INDEX; PRIORITY JOURNAL; TUMOR VOLUME; VAN NUYS SYSTEM;

BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FEMALE; HUMANS; NEOPLASM GRADING; NEOPLASM STAGING; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN-PROTEIN LIGASES;

EID: 80052671044     PISSN: 00917370     EISSN: 15508080     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Ernster VL, Ballard-Barbash R, Barlow WE, Zheng Y, Weaver DL, Cutter G, Yankaskas BC, Rosenberg R, Carney PA, Kerlikowske K, Taplin SH, Urban N, Geller BM. Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst 2002;94:1546-54.
2. Ernster VL, Barclay J, Kerlikowske K, Grady D, Henderson C. Incidence of and treatment for ductal carcinoma in situ of the breast. JAMA 1996;12:913-8.
3. Scott MA, Lagios MD, Axelsson K, Rogers LW, Anderson TJ, Page DL. Ductal carcinoma in situ of the breast: reproducibility of histological subtype analysis. Hum Pathol 1997;28:967-73.
4. Lagios MD, Margolin FR, Westdahl PR, Rose MR. Mammographically detected duct carcinoma in situ. Frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence. Cancer 1989;63:618-24.
5. Tawfik O, Kimler BF, Davis M, Stasik C, Lai SM, Mayo MS, Fan F, Donahues JK, Damjanov I, Thomas P, Connor C, Jewell WR, Smith H, Fabian CJ. Grading invasive ductal carcinoma of the breast: Advantages of using automated proliferation index instead of mitotic count. 2007;450:627-36.
6. Stevens E, Kimler BF, Davis MK, Fan F, Thomas P, Wang XY, Damjanov I, Tawfik OW. www.ncbi.nlm.nih.gov/pubmed/192 01737?ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed. Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_ RVDocSum A newly proposed semi-automated method of grading invasive lobular carcinoma: a unifying concept and correlation with prognostic markers and patient survival. Ann Clin Lab Sci. 2009;39:25-31.
7. Holland R, Peterse JL, Millis RR, Eusebi V, Faverly D, van de Vijer MJ, Zafrani B. Ductal carcinoma in-situ: a proposal for a new classification. Semin Diagn Pathol 1994;11:167-80.
8. Poller DN, Silverstein MJ, Galea M, Locker AP, Elston CW, Blamey RW, Ellis IO. Ideas in pathology. Ductal carcinoma in situ of the breast: a proposal for a new simplified histological classification association between cellular proliferation and c-erbB-2 protein expression. Mod Pathol 1994;7:257-62.
9. Warnberg F, Casalini P, Nordgren H, Bergkvist L, Holmberg L, Menard S. Ductal carcinoma in situ of the breast: a new phenotypic classification system and its relation to prognosis. Breast Cancer Res Treat 2002;73:215-21.
10. Badve S, A'Hern RP, Ward AM, Millis RR, Pinder SE, Ellis IO, Gusterson BA, Sloane JP. Prediction of local recurrence of ductal carcinoma in situ of the breast using five histological classifications: a comparative study with long follow-up. Hum Pathol 1998;29:915-23.
11. Douglas-Jones AG, Gupta SK, Attanoos RL, Morgan JM, Mansel RE. A critical appraisal of six modern classifications of ductal carcinoma in situ of the breast (DCIS): correlation with grade of associated invasive carcinoma. Histopathology 1996; 29:397-409.
12. Ellis IO, Coleman D, Wells C, Kodikare S, Paish EM, Moss S, Al-Sam S, Anderson N, Bobrow L, Buley I, Connolly CE, Dallimore NS, Hales S, Hanby A, Humphreys S, Knoz F, Lowe J, Macartney J, Nash R, Parham D, Patnicj J, Pinder SE, Quinn CM, Robertson AJ, Shrimankar J, Walker RA, Winder R. Impact of a national external quality assessment scheme for breast pathology in the UK. J Clin Pathol 2006;59:138-45.
13. Sneige N, Lagios MD, Schwarting R, Colburn W, Atkinson E, Weber D, Sahin A, Kemp B, Hoque A, Risin S, Sabichi A, Boone C, Dhingra K, Kelloff G, Lippman S. Interobserver reproducibility of the Lagios nuclear grading system for ductal carcinoma in situ. Hum Pathol 2000;30:257-62.
14. Douglas-Jones AG, Morgan JM, Appleton MA, Attanoos RL, Caslin A, Champ CS, Cotter M, Dallimore NS, Dawson A, Fortt RW, Griffiths AP, Hughes M, Kitching PA, O'Brien C, Rashid AM, Stock D, Verghese A, Williams DW, Williams NW, Williams S. Consistency in the observation of features used to classify duct carcinoma in situ (DCIS) of the breast. J Clin Pathol 2000;53:596-602.
15. Bethwaite P, Smith N, Delahunt B, Kenwright D. Reproducibility of new classification schemes for the pathology of ductal carcinoma in situ of the breast. J Clin Pathol 1998;51:450-4.
16. Silverstein MJ, Lagios MD, Craig PH, Waisman JR, Lewiinsky BS, Colburn WJ, Poller DN. A prognostic index for ductal carcinoma in situ of the breast. Cancer 1996;77:2267-74.
17. The consensus conference committee. Consensus conference on the classification of ductal carcinoma in situ. Cancer 1997;80:798-1802.
18. Rehman S, Crow J, Revell P. Bax protein expression in DCIS of the breast in relation to invasive ductal carcinoma and other molecular markers. Pathol Oncol Res 2000;6:256-63.
19. Lebeau A, Unholzer A, Amann G, Kronawitter M, Bauerfeind I, Sendelhofert A, Iff A, Lohrs U. EGFR, HER-2/neu, cyclin D1, p21 and p53 in correlation to cell proliferation and steroid hormone receptor status in ductal carcinoma in situ of the breast. Breast Cancer Res Treat 2003;79:187-98.
20. Hoque A, Menter DG, Sahin AA, Sneige N, Lippman SM. No increased Ki67 expression in ductal carcinoma in situ associated with invasive breast cancer. Cancer Epidemiol Biomark Prev 2001;10:153-4.
21. Ottesen GL, Christensen IJ, Larsen JK, Larsen J, Baldetorp B, Linden T, Hansen B, Andersen J. Carcinoma in situ of the breast: correlation of histopathology to immunohistochemical markers and DNA ploidy. Breast Cancer Res Treat 2000;60:219-26.
22. Bobrow LG, Happerfield LC, Gregory WM, Millis RR. Ductal carcinoma in situ: assessment of necrosis and nuclear morphology and their association with biological markers. J Pathol 1995;176:333-41.